Abstract
Gene amplification, over-expression, and mutation of growth factors, or the receptors themselves, causes increased signaling through receptor kinases, which has been implicated in many human cancers and is associated with poor prognosis. Tumor growth has been shown to be decreased by interrupting this process of extensive growth factor-mediated signaling by directly targeting either the surface receptor or the ligand and thereby preventing cell survival and promoting apoptosis. Monoclonal antibodies have long been eyed as a potential new class of therapeutics targeting cancer and other diseases. Antibody-based therapy initially entered clinical practice when trastuzumab/Herceptin became the first clinically approved drug against an oncogene product as a well-established blocking reagent for tumors with hyperactivity of epidermal growth factor signaling pathways. In the first part of this review we explain basic terms related to the development of antibody-based drugs, give a brief historic perspective of the field, and also touch on topics such as the "humanization of antibodie" or creation of hybrid antibodies. The second part of the review gives an overview of the clinical usage of bispecific antibodies and antibodies "armed"...Continue Reading
Citations
May 31, 2008·Archivum Immunologiae Et Therapiae Experimentalis·Sabine Hombach-KlonischMarek Los
Jul 17, 2008·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Sabine Hombach-KlonischMarek Los
Feb 3, 2007·Cancer Immunology, Immunotherapy : CII·Herbert RiechelmannMichael Schmitt
Oct 3, 2007·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Lee S SchwartzbergArthur C Houts
May 29, 2007·Oncogene·B Bonavida
Feb 21, 2014·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Grant SugiuraWalter Mier
Dec 8, 2006·Expert Opinion on Biological Therapy·Steve H Thorne
Sep 18, 2014·Journal of Hematology & Oncology·Alexandra AroninMichal Elhalel
Oct 15, 2009·European Journal of Pharmacology·Marek Los
Nov 15, 2008·Cancer Treatment Reviews·Dorte Lisbet NielsenClaus Kamby
Aug 21, 2007·European Journal of Pharmacology·Anne ZuseMarek Los
Oct 3, 2006·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Judy E AndersonMarek Los
Jun 29, 2016·Irish Journal of Medical Science·Y LvW Liu
Jul 18, 2006·Molecular & Cellular Proteomics : MCP·Karl E Krueger, Sudhir Srivastava
Apr 7, 2007·Journal of Immunotherapy·Dallas B Flies, Lieping Chen
Sep 1, 2007·Proteomics. Clinical Applications·Sophie DahanMichel Dominguez
Dec 24, 2008·Molecular and Cellular Biology·Subbareddy MaddikaMarek Los
Apr 18, 2017·Biomedit︠s︡inskai︠a︡ khimii︠a︡·M G ZavialovaE N Nikolaev
Jan 11, 2012·Journal of Medicinal Chemistry·Antonio GarofaloPatrick Depreux
Aug 29, 2021·BioFactors·Dina JoharLarry H Bernstein